{
    "Trade/Device Name(s)": [
        "Platelia Lyme IgM",
        "Platelia\u2122 Lyme IgM Assay"
    ],
    "Submitter Information": "Bio-Rad",
    "510(k) Number": "K081362",
    "Predicate Device Reference 510(k) Number(s)": [
        "K894293"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSR"
    ],
    "Summary Letter Date": "June 26, 2008",
    "Summary Letter Received Date": "May 15, 2008",
    "Submission Date": "May 14, 2008",
    "Regulation Number(s)": [
        "21 CFR 866.3830"
    ],
    "Regulation Name(s)": [
        "Treponema pallidum treponemal test reagent"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "serology"
    ],
    "Analyte(s)": [
        "IgM antibodies to Borrelia burgdorferi"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Sodium heparin tube",
        "Sodium citrate tube"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "ELISA"
    ],
    "Methodologies": [
        "Capture immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Bio-Rad Platelia Lyme IgM enzyme immunoassay for presumptive detection of human IgM antibodies to Borrelia burgdorferi in serum or plasma.",
    "Indications for Use Summary": "Qualitative test for presumptive detection of human IgM antibodies to Borrelia burgdorferi in serum or plasma, used as the first step in a two-tiered approach for patients with a history and symptoms of Lyme disease.",
    "fda_folder": "Microbiology"
}